Trophoblast invasion: Lessons from abnormally invasive placenta (placenta accreta)

Journal Pre-proof Trophoblast invasion: Lessons from abnormally invasive placenta (placenta accreta) Nicholas P. Illsley, Sonia C. DaSilva-Arnold, Abdulla Al-Khan, Stacy Zamudio PII:

S0143-4004(20)30011-4

DOI:

https://doi.org/10.1016/j.placenta.2020.01.004

Reference:

YPLAC 4084

To appear in:

Placenta

Received Date: 4 November 2019 Revised Date:

1 January 2020

Accepted Date: 7 January 2020

Please cite this article as: Illsley NP, DaSilva-Arnold SC, Al-Khan A, Zamudio S, Trophoblast invasion: Lessons from abnormally invasive placenta (placenta accreta), Placenta (2020), doi: https:// doi.org/10.1016/j.placenta.2020.01.004. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier Ltd.

1

Trophoblast invasion: lessons from abnormally invasive placenta (placenta accreta)

2 3 4

Nicholas P. Illsley, Sonia C. DaSilva-Arnold, Abdulla Al-Khan, Stacy Zamudio

5 6

Center for Abnormal Placentation, Division of Maternal-Fetal Medicine and Surgery,

7

Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack,

8

NJ, USA

9

10

Abstract

11

The invasion of the uterine wall by extravillous trophoblast is acknowledged as a crucial

12

component of the establishment of pregnancy however, the only part of this process that has been

13

clearly identified is the differentiation of cytotrophoblast (CTB) into the invasive extravillous

14

trophoblast (EVT). The control of invasion, both initiation and termination, have yet to be

15

elucidated and even the mechanism of differentiation is unclear. This review describes our

16

studies which are designed to characterize the intracellular mechanisms that drive differentiation.

17

We have used the over-invasion observed in abnormally invasive placenta (AIP; placenta

18

accreta) to further interrogate this mechanism. Our results show that first trimester CTB to EVT

19

differentiation is accomplished via an epithelial-mesenchymal transition (EMT), with EVT

20

displaying a metastable, mesenchymal phenotype. In the third trimester, while the invasiveness

21

of the EVT is lost, these cells still demonstrate signs of the EMT, albeit diminished. EVT

22

isolated from AIP pregnancies do not however, show the same degree of reduction in EMT

23

shown by normal third trimester cells. They exhibit a more mesenchymal phenotype, consistent

24

with a legacy of greater invasiveness. The master regulatory transcription factor controlling the

25

EMT appears, from the observational data, to be ZEB2 (zinc finger E-box binding protein 2). We

26

verified this by overexpressing ZEB2 in the BeWo and JEG3 trophoblast cell lines and showing

27

that they became more stellate in shape, up-regulated the expression of EMT-associated genes

28

and demonstrated a substantially increased degree of invasiveness. The identification of the

29

differentiation mechanism will enable us to identify the factors controlling invasion and those

30

aberrant processes which generate the abnormal invasion seen in pathologies such as AIP and

31

preeclampsia.

32

Introduction

33

Trophoblast invasion of the uterus is required for fetoplacental development. Invading

34

trophoblast perform multiple essential functions including the anchoring of the placenta to the

35

uterus, regulating maternofetal immune tolerance and conversion of the maternal spiral

36

arterioles, ensuring adequate blood supply to the intervillous space. The mechanisms and

37

regulation of many of these functions remain to be elucidated. Limited access to tissues has

38

restricted research in the human, and the differences between human and rodent invasion

39

processes constrain investigation using the most common animal models. Nonetheless,

40

exploration of invasion in the human can take advantage of natural experiments, pathologies

41

which demonstrate abnormalities of invasion, including the under-invasion seen in preeclampsia

42

and the over-invasion characteristic of Abnormally Invasive Placenta (AIP, aka placenta creta,

43

accreta, increta, percreta and more recently, Placenta Accreta Spectrum or PAS).

44 45

Much of what we know regarding invasion has been observed in preeclampsia, changes such as

46

the absence of integrin switching [1-5] or the loss of matrix metalloproteinases [6, 7]. Much less

47

is known about AIP due in part to its relatively low incidence. Incidence has increased from 1 in

48

30,000 deliveries, as determined in 1937 [8] to approximately 1 in 1000 currently [9-11]. It has

49

become more amenable to investigation, in part through the specialist/referral centers [12]. This

50

review focuses on underlying mechanisms of trophoblast invasion, using AIP as a means of

51

comparative assessment.

52

Placenta previa, uterine damage, access and the route to AIP

53

Much of what we know about AIP has been inferred from the clinical presentation as placental

54

over-invasion. There are a number of important conclusions we can draw from these

55

epidemiological and observational studies. The two primary risk factors for AIP are placenta

56

previa (placenta implanted over the cervix) and some form of utero-myometrial damage, almost

57

always scarring from one or more lower transverse Caesarean sections (LTCS) [9, 10, 13]. With

58

respect to the former risk factor, it has been suggested that the thinner endo-myometrial layer

59

around the cervix in placenta previa is more conducive to trophoblast over-invasion, since it

60

presents a reduced barrier to invading trophoblast [14].

61 62

Uterine damage, such as that caused by Caesarean section, has been posited to promote AIP by

63

providing an acellular, more sparsely populated or less resistant route for trophoblast permeation

64

through the scar (Figure 1B). The two risk factors in combination increase the background

65

population-based risk ~100-fold [15].

66 67

The study by Garmi et al [16] provides some support for uterine injury as a causative factor.

68

Measuring trophoblast invasion in the presence of decidua, they showed that “injured” decidua

69

increased the extent of trophoblast invasion relative to intact decidua. It is important to note

70

however that it is only the myometrium which is likely to be scarred by Caesarean section, since

71

the endometrium will be renewed following pregnancy and subsequently following menses. The

72

question therefore arises of whether there is such a thing as an “injured” decidua. It seems more

73

probable that a globally abnormal decidua may arise due to other factors, genetic,

74

endocrinological etc. (Figure 1C).

75 76

The concept of altered access is also the explanation presented by Tantbirojn and Parast [17], in

77

which they propose that placenta increta and percreta are not due to intrinsically-generated

78

trophoblast over-invasion, but rather arise secondary to Caesarean scar dehiscence. This enables

79

the entry of chorionic villous tissue into the myometrium, potentially allowing extravillous

80

trophoblast access to the deep myometrium. The increased propensity of AIP placentae towards

81

abruption, and also uterine rupture at the site of an old scar supports this hypothesis.

82 83

Other studies [18] have concluded that AIP is not associated with increased capacity for

84

proliferation or invasiveness in trophoblast populations. The conclusion from the combination of

85

these types of studies is that AIP arises primarily from factors such as reduced, absent or

86

abnormal decidua, and/or defective decidualization, leading to increased depth of penetration by

87

(normal) extravillous trophoblast.

88 89

Abnormal invading trophoblast

90

Evidence that changes in the invading trophoblast are associated with absent decidualization is

91

obvious in ectopic (most notably tubal) pregnancy. Trophoblast invasion is unimpeded,

92

demonstrating that extravillous trophoblast possess an intrinsic invasive nature [14, 19, 20], and

93

can differentiate from the parent cytotrophoblast cells in the absence of decidua. There are data

94

showing that trophoblast-specific elements such as growth-, angiogenesis- and invasion-related

95

factors regulate trophoblast invasiveness in AIP [21-24]. Other AIP-associated molecular

96

changes, proposed as factors responsible for trophoblast over-invasion, include abnormalities in

97

secreted extracellular matrix, in secretion of matrix metalloproteinases and in the development of

98

a mesenchymal phenotype [24-27]. There are reasons therefore to believe that a more invasive,

99

or uninhibited (by lack of decidua) invasive trophoblast phenotype is a contributing factor to

100

AIP. While these studies demonstrate up-regulation of trophoblast invasiveness in AIP, in many

101

of these cases it is possible that environmental cues may be responsible for the alterations

102

observed. We believe it is quite probable that both arguments are correct, that both altered access

103

and increased trophoblast invasiveness may be involved in the pathogenesis of AIP.

104 105

Is there a reason therefore to think that defects exist at the molecular level beyond the well-

106

recognized risk factors? Aside from the importance of the risk factors, is the obvious fact that the

107

existence of these risk factors in a pregnancy does not automatically lead to AIP. There are many

108

pregnancies in which the presence of placenta previa in subjects who have had multiple

109

Caesarean sections does not result in AIP. Clearly while the risk factors are important pre-

110

disposing components, they do not appear to tell the entire story. It seems likely that some other

111

element or elements, interacting with the effects of placenta previa and uterine damage, complete

112

the equation necessary for AIP causation. This is the root of our molecular investigations into

113

AIP pathogenesis.

114 115

Exploring the underlying mechanism

116

Many of the in vitro studies of trophoblast invasion have been based not on an underlying

117

mechanism, but rather on association with isolated invasion-related factors. The wealth of studies

118

examining the under-invasion in preeclampsia has identified many candidate genes involved in

119

the invasion process and therefore possible targets for investigation. Many of these studies are

120

focused on the development of the invasive cells, the extravillous trophoblast and their

121

properties. Alterations in processes such as the conversion of trophoblast from CTB through pre-

122

EVT cell types such as cell column trophoblast, the control of EVT movement through the

123

decidua and the transformation of active EVT into the non-motile multinuclear trophoblast giant

124

cells may all contribute in the development of invasion abnormalities. We have chosen to

125

investigate the differentiation of cytotrophoblast into extravillous trophoblast, the process by

126

which non-motile polarized cells anchored to a basal lamina are converted to non-polarized,

127

anchorage-independent invasive cells.

128 129

AIP is an invasion pathology and many investigative attempts have focused on alterations in the

130

extravillous trophoblast (EVT) infiltration of the uterus or factors regulating EVT invasion [28-

131

34]. It important to realize that currently we have incomplete understanding of the processes

132

involved in the normal invasion process. We have minimal understanding of the regulatory

133

elements controlling the promotion and inhibition of invasion, no matter the aberrant control that

134

is a feature of AIP. Research into AIP therefore is, in part, research into the invasion process

135

itself, as well as an attempt to isolate those components which demonstrate abnormal function.

136

There is a substantial literature addressing trophoblast invasion, but it is drawn in large part from

137

research into the under-invasion characteristic of preeclampsia. Much of this invasion literature

138

is focused on the role played by specific genes/proteins. However, in many cases, these genes or

139

proteins have not been examined functionally or have not been shown to vary as a result of

140

invasion pathologies in vivo, raising the question of physiological relevance. This is important

141

because as a complex, multi-component process, it is possible to compromise trophoblast

142

invasion in vitro by modifying a single component, whether or not such a modification occurs in

143

vivo. Nevertheless, it is possible to glean from these reports, information related to the invasion

144

processes, allowing us to build a picture of the components of the normal invasive mechanisms.

145 146

We have been investigating the molecular changes in normal and abnormal invasion, starting

147

with studies comparing CTB and EVT in the first and third trimesters [35, 36]. We focused on

148

normal processes which might be subverted in AIP (and possibly in preeclampsia). One clear

149

option is disruption of the fundamental mechanism of normal CTB-EVT differentiation, the

150

epithelial-mesenchymal transition (EMT). The idea that the differentiation of cytotrophoblast

151

into extravillous trophoblast might be an EMT has been extant for many years and there has been

152

sporadic evidence presented for this concept. [1, 37-43]. However, it is only more recently that

153

we have explored this idea to the degree necessary for definitive identification of the process and

154

classification within the range of EMT types already identified [44].

155 156

Our initial studies interrogated first trimester CTB and EVT to determine if the differences

157

between them indicated the existence of an EMT as the mechanism of differentiation. We thus

158

examined the expression, in CTB and EVT, of 84 genes associated with EMT, to determine if

159

changes in these genes could provide evidence of an EMT in this differentiation process. The

160

results showed quite clearly that many of the gene expression changes were characteristic of an

161

EMT (Table 1) [35]. On the EMT-associated PCR array we used, there were also genes which

162

showed no change or a change opposite to that which might be expected from other well-

163

characterized EMT types. We attribute this, at least in part, to the breadth and variation within

164

the EMT process. Many of the genes in the PCR array were drawn from the best-investigated

165

examples of EMT, primarily cancer metastasis. Many of these genes might not be expected to

166

form part of a normal trophoblast EMT process. Our data supports that the CTB/EVT

167

differentiation process is a unique type of EMT, separate from those previously identified

168

(gastrulation, wound healing, metastasis). Certainly, it has some unique characteristics, such as

169

the down-regulation of TWIST1. This transcription factor, generally acknowledged as a master

170

EMT regulator, is associated in the trophoblast system with the development of

171

syncytiotrophoblast cells rather than the lineage pathway leading to EVT [45, 46]. In addition,

172

EVT not only retain but up-regulate the expression of cytokeratins 7, 14 and 19, elements

173

identified as epithelial markers, which are frequently lost in other EMT types during the

174

transition to a mesenchymal phenotype. This suggests the progression of trophoblast to a

175

metastable cell type within the EMT spectrum (Figure 2), capable of further movement, forward

176

to a more mesenchymal phenotype or backward, to the epithelial phenotype [47]. We speculate

177

that CTB differentiation may be the molecular archetypal EMT, a “type 0” EMT, as it occurs so

178

early in human development compared to EMT types 1-3 [44, 48].

179 180

EMT status in the third trimester

181

Like preeclampsia, AIP is generally only identified and accessible in the late second and third

182

trimester. While the invasion process has been long-completed at this point, we hypothesized

183

that third trimester EVT cells from AIP pregnancies might still reflect the abnormal process that

184

occurred in the first and second trimesters. We analyzed CTB/EVT differences in normal third

185

trimester pregnancies, as a precursor to the analysis of AIP. When we compared CTB and EVT

186

from normal term pregnancies, we found that while signs of an EMT were still apparent, many of

187

the gene expression changes observed in the first trimester were much reduced compared to the

188

third trimester profile (Table 2) [36]. We concluded that the EVT had regressed from the first

189

trimester position on the EMT spectrum to one closer to that of the CTB (Figure 2).

190 191

Trophoblast differentiation in AIP

192

In the next stage we undertook analysis of AIP. There are important issues in the investigation of

193

AIP that merit consideration. Although the incidence of AIP is rising, it is still a relatively rare

194

pathology compared to other placental pathologies of pregnancy. Acquiring sufficient samples

195

usually requires access to a referral center. In addition, use of the optimum validation of

196

histopathological analysis is crucial. Clinical, post-surgical reports are inadequate validation of

197

an AIP; histopathological evaluation is the recommended method of assessment and

198

classification, necessary to decide whether a case is truly AIP and to determine the severity of

199

AIP (i.e. accreta, increta, percreta, Grades 1, 2 or 3 on the recent FIGO Clinical Classification

200

System; [49]). Published reports lacking histopathological analysis and/or stratification by AIP

201

grade are always subject to the question of whether results have been obtained from a mixture of

202

normal and pathological samples or a mixture of pathologies. For this reason, we conduct our

203

research using samples from cases where histopathological analysis has confirmed the presence

204

of either placenta increta or placenta percreta (i.e. placental villi within the muscular fibers and

205

sometimes in the lumen of the deep uterine vasculature or villous tissue within or breaching the

206

uterine serosa).

207 208

Another important issue is that of controls. National clinical professional organizations

209

recommend delivery of AIP cases at 34-36 weeks, before bleeding or other instability becomes

210

an issue. Use of term pregnancies as controls raises questions of gestational age effects. Use of

211

age-matched cases of preterm birth raises the issue of the causal elements that lead to preterm

212

birth as potentially confounding factors. For our controls we used cells prepared from cases of

213

placenta previa, where the placental is implanted over the cervix and is also often delivered

214

before term, usually, as in AIP, due to potential risk of vaginal bleeding. Unlike preterm birth

215

controls, the previa cases are electively delivered because of the mechanical obstruction

216

presented to delivery by the placenta. There are no metabolic, endocrine or unknown causal

217

issues associated with the previa cases. They are delivered before term to mitigate the risk of

218

events such as abruption/hemorrhage. All our AIP pregnancies also had placenta previa, and

219

were delivered around the same gestational age, making the previa cases ideal controls for AIP

220

pregnancies.

221 222

Supporting the use of previas as controls, when we compared EVT from placenta previa with

223

normal term EVT, we found only 3 changes out of 84 genes, 2 of which were changes of less

224

than 1.5-fold. This supports that normal and previa EVT are very similar, at least with respect to

225

this set of EMT-related genes. Using CTB and EVT from the placenta previa cases as controls,

226

we then compared them with the same cells from cases of AIP (all percreta, Grade 3a, 3b of the

227

FIGO classification). While there were no differences between CTB from placenta previa and

228

AIP cases, multiple differences were found between AIP and control EVT (Table 3)[36]. These

229

included loss of CDH1 and increased MMP2, TGFß2 and ZEB2, changes associated with an

230

EMT. EVT obtained from AIP are thus shifted towards the mesenchymal end of the EMT

231

spectrum compared to placenta previa or normal term EVT (Figure 2), although they clearly

232

show less of a mesenchymal phenotype than first trimester EVT. These data do not permit

233

determination as to whether this resulted from an increased mesenchymal shift in EVT from AIP

234

pregnancies during the first/second trimester, or whether the EVT-AIP were simply less affected

235

by the factors causing regression of EMT status towards the epithelial end of the spectrum during

236

the second/third trimester.

237 238

Regulation of the EMT

239

As part of the analysis of EMT genes, we analyzed the expression of multiple EMT “master

240

regulator” transcription factors (FOXC2, GSC, TWIST1, SNA1, SNA2, ZEB1, ZEB2) [50, 51].

241

Only ZEB2 (zinc finger E-box binding protein 2) displayed characteristics which matched with

242

both the invasiveness of cells in vivo and with EMT status. The other master regulators either

243

showed no change or changes which were inconsistent with invasiveness. This was surprising,

244

because ZEB2 has generally been regarded as a suppressive transcriptional regulator, associated

245

primarily with the down-regulation of epithelial genes such as CDH1 (E-cadherin) [52-54]. In

246

first trimester trophoblast however, ZEB2 is increased by almost 200-fold in EVT compared to

247

CTB but, in the third trimester, drops back to a level below that of third trimester CTB [35, 36].

248

In AIP however, EVT levels of ZEB2 remain elevated compared to the corresponding control

249

(placenta previa) EVT, consistent with the more mesenchymal phenotype of cells from the AIP

250

placenta [36].

251 252

Drawing from these data, we hypothesized that the ZEB2 transcription factor was responsible for

253

regulating progress of trophoblast cells through the EMT. This is consistent with the levels of

254

ZEB2 in trophoblast cell lines; the non-invasive BeWo and the minimally invasive JEG3

255

choriocarcinoma lines have low gene expression levels of ZEB2 compared to the much higher

256

level of ZEB2 encountered in the invasive HTR8/SVneo model EVT cell line [36]. To test this

257

hypothesis, we overexpressed ZEB2 in BeWo and JEG3 cells and isolated clonal lines. The two

258

clones showing highest expression of ZEB2 (> 40-fold increase in expression) demonstrated the

259

changes in morphology, gene expression and invasiveness characteristic of a mesenchymal shift

260

in EMT status, while lower ZEB2-expressing clones were not affected [55]. This supports our

261

hypothesis with respect to the role of ZEB2 and leads us to conclude that we have identified a

262

major mechanism controlling the CTB/EVT differentiation process, leading to the development

263

of invasive cells. We note also that other systems including the Wnt signaling pathway and

264

transcriptional factors such as STOX1 may play similar roles in regulating EMT-driven

265

trophoblast invasiveness [56-58]; further research is necessary to integrate these elements into a

266

coherent mechanism.

267 268

Effects of the uterine environment

269

Several groups have suggested that cell-cell interaction, either through direct contact or through

270

secreted factors, is responsible for regulating invasion. There are reports showing that

271

conditioned medium from decidual natural killer cells (dNK) promotes invasion [59-61]. dNK

272

have been shown to be present at their highest level early in gestation and to decline over

273

gestation [62, 63]. However, very reduced dNK cell numbers were observed in near-term AIP

274

compared to previa controls [64], suggesting that any invasion-promoting properties are

275

minimized or no longer relevant later in gestation. By contrast, another study showed no change

276

in dNK in AIP, but an increase in T-regulatory lymphocytes and significantly fewer immature,

277

non-activated dendritic cells [32]. There is no clear evidence for the limitation of invasion via

278

cell-cell interaction although, as noted above, in the absence of a decidual/myometrial layer,

279

trophoblast continues to invade, suggesting some form of trophoblast/decidual interaction is at

280

the root of the restrictions on invasion [59, 65-68].

281

282

Conclusions

283

Despite the evidence for extra-trophoblastic etiologic factors, most of the limited research being

284

performed into causes of AIP has generally been directed towards discovery of factors that

285

increase trophoblast invasiveness. Less attention has been paid to potential interactions of the

286

invading trophoblast with a reduced or defective decidual layer, but recent research shows that

287

changes in the decidual/myometrial environment surrounding the trophoblast may have major

288

effects on trophoblast function. Investigators have already stepped back from pregnancy to

289

explore the possibility that the uterine environment pre-pregnancy may reflect differences which

290

lead to the pathological effects in preeclamptic pregnancy [69, 70]. Similar circumstances may

291

also result in the identification of pre-pregnancy elements which, when added to uterine damage

292

and placenta previa, lead to AIP. As described above, there has been a continuing debate over the

293

question of whether aberrant extravillous trophoblast is the causal element in over-invasion, as

294

opposed to defective decidual/uterine components which enable over-invasion. By extension, it

295

is the possible that those uterine characteristics which influence the invasion process toward AIP

296

may also be apparent in the non-pregnant state. Under these circumstances, intervention to

297

modify these characteristics, pre-pregnancy, might also be possible. To explore these avenues, it

298

is necessary that we understand the mechanisms of over-invasion and the forces driving it, hence

299

the need to determine the molecular etiology

300 301

Our data provide a clearer definition of the EMT as a mechanism for CTB/EVT differentiation.

302

Final confirmation and definition awaits a more in-depth assessment of the gene expression

303

profile in the differentiation process. Nevertheless, we believe we now have a tool by which to

304

assess the extracellular signals that regulate the differentiation status of these cells and, by

305

extension, their invasiveness. The changes in gene expression characteristic of the EMT in

306

trophoblast will enable us to assess the effect of regulatory elements, not simply using one or two

307

parameters but on the basis of the process by which these cells control their phenotype, including

308

morphology and invasiveness. We now have a model of the EMT spectrum, the alterations

309

observed in AIP and the potential for movement within that spectrum leading to changes in

310

invasiveness that are pathophysiologically relevant to both AIP and preeclampsia. It will now be

311

possible to focus on those agents in pathologies which shift cells across the EMT spectrum. It

312

will be instructive to determine whether similar shifts, but toward the epithelial phenotype, are

313

found in EVT from cases of preeclampsia, especially the severe early-onset, placenta-associated

314

form of the disease. There are suggestions that the under-invasiveness observed in preeclampsia

315

may also involve the EMT spectrum, as markers of the reverse process, mesenchymal-epithelial

316

transition, have been observed [71]. The EMT provides a solid mechanistic basis for the

317

abnormally invasive pathologies and for investigations of the defects, trophoblastic or uterine,

318

which are causal.

319

320

References

321 322

1.

323 324

differentiation. Acta Anat (Basel);156(3):202-216. 2.

325 326

Vicovac L, Aplin JD. (1996) Epithelial-mesenchymal transition during trophoblast

Vicovac L, Jones CJ, Aplin JD. (1995) Trophoblast differentiation during formation of anchoring villi in a model of the early human placenta in vitro. Placenta;16(1):41-56.

3.

Damsky CH, Fitzgerald ML, Fisher SJ. (1992) Distribution patterns of extracellular matrix

327

components and adhesion receptors are intricately modulated during first trimester

328

cytotrophoblast differentiation along the invasive pathway, in vivo. Journal of Clinical

329

Investigation;89(1):210-222.

330

4.

Damsky CH, Librach C, Lim KH, Fitzgerald ML, McMaster MT, Janatpour M, Zhou Y,

331

Logan SK, Fisher SJ. (1994) Integrin switching regulates normal trophoblast invasion.

332

Development;120(12):3657-3666.

333

5.

334 335

Burrows T, King A, Loke Y. (1996) Trophoblast migration during human placental implantation. Hum Reprod Update;3(4):307-323.

6.

Reister F, Kingdom JC, Ruck P, Marzusch K, Heyl W, Pauer U, Kaufmann P, Rath W,

336

Huppertz B. (2006) Altered protease expression by periarterial trophoblast cells in severe

337

early-onset preeclampsia with IUGR. J Perinat Med;34(4):272-279.

338

7.

Li X, Wu C, Shen Y, Wang K, Tang L, Zhou M, Yang M, Pan T, Liu X, Xu W. (2018) Ten-

339

eleven translocation 2 demethylates the MMP9 promoter, and its down-regulation in

340

preeclampsia impairs trophoblast migration and invasion. J Biol Chem;293(26):10059-

341

10070.

342

8.

Irving F, Hertig A. (1937) A study of placenta accreta. Surg Gynec Obst;64:178.

343 344 345 346 347

9.

Silver RM, Branch DW. (2018) Placenta Accreta Spectrum. N Engl J Med;378(16):15291536.

10. Carusi DA. (2018) The Placenta Accreta Spectrum: Epidemiology and Risk Factors. Clinical obstetrics and gynecology;61(4):733-742. 11. Jauniaux E, Bunce C, Gronbeck L, Langhoff-Roos J. (2019) Prevalence and main outcomes

348

of placenta accreta spectrum: a systematic review and metaanalysis. Am J Obstet Gynecol.

349

12. Al-Khan A, Gupta V, Illsley NP, Mannion C, Koenig C, Bogomol A, Alvarez M, Zamudio

350

S. (2014) Maternal and fetal outcomes in placenta accreta after institution of team-managed

351

care. Reprod Sci;21(6):761-771.

352

13. Beuker JM, Erwich JJ, Khong TY. (2005) Is endomyometrial injury during termination of

353

pregnancy or curettage following miscarriage the precursor to placenta accreta? J Clin

354

Pathol;58(3):273-275.

355 356 357

14. Benirschke K, Kaufmann P, Baergen RN. (2006) Pathology of the human placenta; 5th Edition; New York: Springer. 15. Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, Moawad AH, Caritis

358

SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM,

359

O'Sullivan MJ, Sibai B, Langer O, Thorp JM, Ramin SM, Mercer BM, National Institute of

360

Child H, Human Development Maternal-Fetal Medicine Units N. (2006) Maternal morbidity

361

associated with multiple repeat cesarean deliveries. Obstet Gynecol;107(6):1226-1232.

362

16. Garmi G, Goldman S, Shalev E, Salim R. (2011) The effects of decidual injury on the

363

invasion potential of trophoblastic cells. Obstetrics & Gynecology;117(1):55-59.

364 365

17. Tantbirojn P, Crum CP, Parast MM. (2008) Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta;29(7):639-645.

366 367 368 369 370 371

18. Earl U, Bulmer JN, Briones A. (1987) Placenta accreta: an immunohistological study of trophoblast populations. Placenta;8(3):273-282. 19. Randall S, Buckley CH, Fox H. (1987) Placentation in the fallopian tube. Int J Gynecol Pathol;6:132-139. 20. Robertson WB, Brosens I, Landells WN. (1985) Abnormal placentation. Pathol Annu;14:411-426.

372

21. Khong T, WB R. (1987) Placenta creta and placenta praevia creta. Placenta;8(4):399-409.

373

22. Tseng JJ, Chou MM. (2006) Differential expression of growth-, angiogenesis- and invasion-

374

related factors in the development of placenta accreta. Taiwanese journal of obstetrics &

375

gynecology;45(2):100-106.

376

23. Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. (2006) Differential expression

377

of vascular endothelial growth factor, placenta growth factor and their receptors in placentae

378

from pregnancies complicated by placenta accreta. Placenta;27(1):70-78.

379

24. Wehrum MJ, Buhimschi IA, Salafia C, Thung S, Bahtiyar MO, Werner EF, Campbell KH,

380

Laky C, Sfakianaki AK, Zhao G, Funai EF, Buhimschi CS. (2011) Accreta complicating

381

complete placenta previa is characterized by reduced systemic levels of vascular endothelial

382

growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.

383

American Journal of Obstetrics & Gynecology;204(5):411.e411-411.e411.

384

25. Tseng JJ, Hsu SL, Wen MC, Ho ES, Chou MM. (2004) Expression of epidermal growth

385

factor receptor and c-erbB-2 oncoprotein in trophoblast populations of placenta accreta.

386

American Journal of Obstetrics & Gynecology;191(6):2106-2113.

387

26. Kocarslan S, Incebiyik A, Guldur ME, Ekinci T, Ozardali HI. (2015) What is the role of

388

matrix metalloproteinase-2 in placenta percreta? Journal of Obstetrics & Gynaecology

389

Research;41(7):1018-1022.

390

27. Tseng JJ, Hsieh YT, Hsu SL, Chou MM. (2009) Metastasis associated lung adenocarcinoma

391

transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with

392

trophoblast-like cell invasion in vitro. Mol Hum Reprod;15(11):725-731.

393

28. Goshen R, Ariel I, Shuster S, Hochberg A, Vlodavsky I, de Groot N, Ben-Rafael Z, Stern R.

394

(1996) Hyaluronan, CD44 and its variant exons in human trophoblast invasion and placental

395

angiogenesis. Mol Hum Reprod;2(9):685-691.

396

29. Goldman-Wohl DS, Ariel I, Greenfield C, Hanoch J, Yagel S. (2000) HLA-G expression in

397

extravillous trophoblasts is an intrinsic property of cell differentiation: a lesson learned from

398

ectopic pregnancies. Mol Hum Reprod;6(6):535-540.

399 400 401

30. Kim KR, Jun SY, Kim JY, Ro JY. (2004) Implantation site intermediate trophoblasts in placenta cretas. Mod Pathol;17(12):1483-1490. 31. Umemura K, Ishioka S, Endo T, Ezaka Y, Takahashi M, Saito T. (2013) Roles of

402

microRNA-34a in the pathogenesis of placenta accreta. Journal of Obstetrics &

403

Gynaecology Research;39(1):67-74.

404 405

32. Schwede S, Alfer J, von Rango U. (2014) Differences in regulatory T-cell and dendritic cell pattern in decidual tissue of placenta accreta/increta cases. Placenta;35(6):378-385.

406

33. Shirakawa T, Miyahara Y, Tanimura K, Morita H, Kawakami F, Itoh T, Yamada H. (2015)

407

Expression of Epithelial-Mesenchymal Transition-related Factors in Adherent Placenta.

408

International Journal of Gynecological Pathology;34(6):584-589.

409

34. Chen Y, Zhang H, Han F, Yue L, Qiao C, Zhang Y, Dou P, Liu W, Li Y. (2018) The

410

depletion of MARVELD1 leads to murine placenta accreta via integrin beta4-dependent

411

trophoblast cell invasion. Journal of cellular physiology;233(3):2257-2269.

412

35. DaSilva-Arnold S, James JL, Al-Khan A, Zamudio S, Illsley NP. (2015) Differentiation of

413

first trimester cytotrophoblast to extravillous trophoblast involves an epithelial-

414

mesenchymal transition. Placenta;36(12):1412-1418.

415

36. DaSilva-Arnold SC, Zamudio S, Al-Khan A, Alvarez-Perez J, Mannion C, Koenig C, Luke

416

D, Perez AM, Petroff M, Alvarez M, Illsley NP. (2018) Human trophoblast epithelial-

417

mesenchymal transition in abnormally invasive placenta. Biol Reprod;99(2):409-421.

418 419 420

37. Aplin JD. (1993) Expression of integrin alpha 6 beta 4 in human trophoblast and its loss from extravillous cells. Placenta;14(2):203-215. 38. Floridon C, Nielsen O, Holund B, Sunde L, Westergaard JG, Thomsen SG, Teisner B.

421

(2000) Localization of E-cadherin in villous, extravillous and vascular trophoblasts during

422

intrauterine, ectopic and molar pregnancy. Mol Hum Reprod;6(10):943-950.

423

39. Kokkinos MI, Murthi P, Wafai R, Thompson EW, Newgreen DF. (2010) Cadherins in the

424

human placenta--epithelial-mesenchymal transition (EMT) and placental development.

425

Placenta;31(9):747-755.

426

40. Davies JE, Pollheimer J, Yong HE, Kokkinos MI, Kalionis B, Knofler M, Murthi P. (2016)

427

Epithelial-mesenchymal transition during extravillous trophoblast differentiation. Cell Adh

428

Migr;10(3):310-321.

429

41. Demir-Weusten A, Seval Y, Kaufmann P, Demir R, Yucel G, Huppertz B. (2007) Matrix

430

metalloproteinases-2, -3 and -9 in human term placenta. Acta Histochemica;109:403-412.

431

42. Shokry M, Omran O, Hassan H, Elsedfy G, Husseian M. (2009) Expression of matrix

432

metalloproteinases 2 and 9 in human trophoblasts of normal and preeclamptic placentas:

433

Preliminary findings. Exp Mol Path;87:219-225.

434

43. Huppertz B, Kertchanska S, Demir A, Frank H, Kaufmann P. (1998) Immunohistochemisty

435

of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during

436

trophoblast invasion in the human placenta. Cell Tissue Res;291:133-148.

437 438 439

44. Zeisberg M, Neilson EG. (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest;119(6):1429-1437. 45. Ng YH, Zhu H, Leung PC. (2011) Twist regulates cadherin-mediated differentiation and

440

fusion of human trophoblastic cells. The Journal of clinical endocrinology and

441

metabolism;96(12):3881-3890.

442 443 444 445 446 447 448

46. Lu X, He Y, Zhu C, Wang H, Chen S, Lin HY. (2016) Twist1 is involved in trophoblast syncytialization by regulating GCM1. Placenta;39:45-54. 47. Tam WL, Weinberg RA. (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature medicine;19(11):1438-1449. 48. Kalluri R, Weinberg RA. (2009) The basics of epithelial-mesenchymal transition. J Clin Invest;119(6):1420-1428. 49. Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S, Diagnosis FPA,

449

Management Expert Consensus P. (2019) FIGO classification for the clinical diagnosis of

450

placenta accreta spectrum disorders. Int J Gynaecol Obstet;146(1):20-24.

451 452

50. De Craene B, Berx G. (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer;13(2):97-110.

453 454 455

51. Zheng H, Kang Y. (2014) Multilayer control of the EMT master regulators. Oncogene;33(14):1755-1763. 52. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M,

456

Huylebroeck D, van Roy F. (2001) The two-handed E box binding zinc finger protein SIP1

457

downregulates E-cadherin and induces invasion. Mol Cell;7(6):1267-1278.

458

53. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, Tulchinsky

459

E, Van Roy F, Berx G. (2005) SIP1/ZEB2 induces EMT by repressing genes of different

460

epithelial cell-cell junctions. Nucleic Acids Res;33(20):6566-6578.

461 462 463

54. Vandewalle C, Van Roy F, Berx G. (2009) The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci;66(5):773-787. 55. DaSilva-Arnold SC, Kuo CY, Davra V, Remache Y, Kim PCW, Fisher JP, Zamudio S, Al-

464

Khan A, Birge RB, Illsley NP. (2019) ZEB2, a master regulator of the epithelial-

465

mesenchymal transition, mediates trophoblast differentiation. Mol Hum Reprod;25(2):61-

466

75.

467 468 469

56. Knofler M, Pollheimer J. (2013) Human placental trophoblast invasion and differentiation: a particular focus on Wnt signaling. Front Genet;4:190. 57. Visser A, Beijer M, Oudejans CBM, van Dijk M. (2018) The effect of maternal NODAL on

470

STOX1 expression in extravillous trophoblasts is mediated by IGF1. PLoS

471

One;13(8):e0202190.

472

58. van Dijk M, van Bezu J, van Abel D, Dunk C, Blankenstein MA, Oudejans CB, Lye SJ.

473

(2010) The STOX1 genotype associated with pre-eclampsia leads to a reduction of

474

trophoblast invasion by alpha-T-catenin upregulation. Hum Mol Genet;19(13):2658-2667.

475

59. Wallace AE, Host AJ, Whitley GS, Cartwright JE. (2013) Decidual natural killer cell

476

interactions with trophoblasts are impaired in pregnancies at increased risk of preeclampsia.

477

Am J Pathol;183(6):1853-1861.

478 479 480

60. Lash GE, Robson SC, Bulmer JN. (2010) Review: Functional role of uterine natural killer (uNK) cells in human early pregnancy decidua. Placenta;31 Suppl:S87-92. 61. Ma L, Li G, Cao G, Zhu Y, Du MR, Zhao Y, Wang H, Liu Y, Yang Y, Li YX, Li DJ, Yang

481

H, Wang YL. (2017) dNK cells facilitate the interaction between trophoblastic and

482

endothelial cells via VEGF-C and HGF. Immunol Cell Biol;95(8):695-704.

483 484 485 486 487

62. Bulmer JN, Williams PJ, Lash GE. (2010) Immune cells in the placental bed. Int J Dev Biol;54(2-3):281-294. 63. Williams P, Searle R, Robson S, Innes B, Bulmer J. (2009) Decidual leucocyte populations in early to late gestation normal human pregnancy. J Reprod Immunol;82(1):24-31. 64. Laban M, Ibrahim EA, Elsafty MS, Hassanin AS. (2014) Placenta accreta is associated with

488

decreased decidual natural killer (dNK) cells population: a comparative pilot study.

489

European Journal of Obstetrics, Gynecology, & Reproductive Biology;181:284-288.

490

65. Zhu XM, Han T, Sargent IL, Wang YL, Yao YQ. (2009) Conditioned medium from human

491

decidual stromal cells has a concentration-dependent effect on trophoblast cell invasion.

492

Placenta;30(1):74-78.

493

66. Hannon T, Innes BA, Lash GE, Bulmer JN, Robson SC. (2012) Effects of local decidua on

494

trophoblast invasion and spiral artery remodeling in focal placenta creta - An

495

immunohistochemical study. Placenta;33(12):998-1004.

496

67. Menkhorst EM, Lane N, Winship AL, Li P, Yap J, Meehan K, Rainczuk A, Stephens A,

497

Dimitriadis E. (2012) Decidual-secreted factors alter invasive trophoblast membrane and

498

secreted proteins implying a role for decidual cell regulation of placentation. PLoS

499

One;7(2):e31418.

500 501 502

68. Lash GE. (2015) Molecular Cross-Talk at the Feto-Maternal Interface. Cold Spring Harb Perspect Med;5(12). 69. Rabaglino MB, Post Uiterweer ED, Jeyabalan A, Hogge WA, Conrad KP. (2015)

503

Bioinformatics approach reveals evidence for impaired endometrial maturation before and

504

during early pregnancy in women who developed preeclampsia. Hypertension;65(2):421-

505

429.

506

70. Garrido-Gomez T, Dominguez F, Quinonero A, Diaz-Gimeno P, Kapidzic M, Gormley M,

507

Ona K, Padilla-Iserte P, McMaster M, Genbacev O, Perales A, Fisher SJ, Simon C. (2017)

508

Defective decidualization during and after severe preeclampsia reveals a possible maternal

509

contribution to the etiology. Proc Natl Acad Sci U S A;114(40):E8468-E8477.

510

71. Du L, Kuang L, He F, Tang W, Sun W, Chen D. (2017) Mesenchymal-to-epithelial

511 512 513

transition in the placental tissues of patients with preeclampsia. Hypertens Res;40(1):67-72.

1

Figure Legends

2 3

Figure 1: Models of extravillous trophoblast trans-uterine access. The figure shows the potential

4

pathways for extravillous trophoblast (EVT) movement across the decidua from the anchoring

5

villous tip into the myometrium. The figure shows normal pregnancy (A), a pregnancy where

6

uterine damage, such as a Caesarean section, has left a scar across the uterus (B) and a pregnancy

7

where the decidual cell population is altered in terms of either numbers or function (C)

8 9

Figure 2: The trophoblast epithelial-mesenchymal transition (EMT) spectrum. The spectrum of

10

the EMT reaches from epithelia to mesenchymal. Cytotrophoblast are at the epithelial end, while

11

first trimester EVT are situated well towards, but not at, the mesenchymal pole. Third trimester

12

EVT show a regression, back along the spectrum towards the epithelial (cytotrophoblastic) end.

13

EVT obtained from AIP pregnancies do not show the same degree of regression and are placed

14

towards the mesenchymal end of the spectrum compared to normal or placenta previa controls.

15

Table 1: First trimester EMT gene changes (CTB to EVT) Down-regulated genes

Up-regulated genes

Gene ID BMP7 CDH1 CTNNB1 EGFR FOXC2 FZD7 JAG1 OCLN SNAI1 SNAI2 TWIST1 WNT5A

Gene ID FN1 ITGA5 ITGB1 KRT14 KRT19 KRT7 MMP2 MMP3 MMP9 NOTCH1 SNAI3 SPARC SPP1 TCF4 TFPI2 TGFB1 TGFB2 TIMP1 VIM WNT5B ZEB2

Fold change -44.1 -7.1 -5.2 -23.8 -57.8 -11.5 -30.1 -35.2 -2.3 -10.6 -8.8 -14.6

Fold change 106.9 139.7 4.3 41.4 6.2 2.7 356.8 128.9 160.4 6.4 4.3 4.9 186.3 18.4 24.4 47.7 115.1 24.5 235.2 3.0 198.5

The genes in this table all demonstrated significant differential expression in first trimester EVT compared to first trimester CTB controls. Analysis by t test or Mann-Whitney U test. p < 0.05; n= 6, 6. Data from reference 35

Table 2: Third trimester EMT gene changes (CTB to EVT) Down-regulated genes

Up-regulated genes

Gene ID BMP7 CDH1 COL1A2 CTNNB1 EGFR F11R FOXC2 FZD7 JAG1 MMP9 NOTCH1 OCLN SPP1 TWIST1 ZEB2

Gene ID FN1 IGFBP4 ITGA5 ITGB1 KRT19 KRT7 MMP2 MMP3 PDGFRB SNAI1 SNAI2 SPARC STAT3 TCF4 TFPI2 TGFB1 TGFB2 TIMP1

Fold change -34.0 -1.5 21.9 -6.3 -4.1 2.6 -3.6 -4.1 -9.2 -7.2 -2.8 -32.9 -5.9 -14.3 -3.3

Fold change 59.8 32.4 38.6 4.0 6.6 2.7 203.9 29.6 60.8 5.0 24.7 46.8 2.5 2.1 3.0 9.1 34.7 43.1

The genes in this table all demonstrated significant differential expression in third trimester EVT compared to third trimester CTB controls. Analysis by t test or Mann-Whitney U test. p < 0.05; n= 8, 8. Data from reference 36.

Table 3: Third trimester EMT gene changes (EVT-previa to EVT-AIP) Gene ID

Fold change

CDH1 CDH2 COL3A1 KRT14 MMP2 PLEK2 SNAI2 SPARC SPP1 STAT3 TFPI2 TGFB2 WNT11 ZEB2

-1.45 2.34 3.94 1.76 3.74 4.87 8.88 1.59 2.09 1.30 2.20 1.85 3.32 4.12

The genes in this table all demonstrated significant differential expression in EVT from AIP pregnancies compared to EVT from placenta previa controls. Analysis by t test or Mann-Whitney U test. p < 0.05; n= 8, 8. Data from reference 36.